请求分享药物化学专业英语资料

到资料中心下载－药物化学英文讲义

请问:除了英文讲义..有没有英文的教材呢?非常感谢

Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacology involved with designing, synthesizing and developing pharmaceutical drugs. Medicinal chemistry involves the identification, synthesis and development of new chemical entities suitable for therapeutic use. It also includes the study of existing drugs, their biological properties, and their quantitative structure-activity relationships (QSAR). Pharmaceutical chemistry is focused on quality aspects of medicines and aims to assure fitness for the purpose of medicinal products.

Medicinal chemistry is a highly interdisciplinary science combining organic chemistry with biochemistry, computational chemistry, pharmacology, pharmacognosy, molecular biology, statistics, and physical chemistry.

Process of drug discovery

Discovery
The first step of drug discovery involves the identification of new active compounds, often called "hits", which are typically found by screening many compounds for the desired biological properties. These hits can come from natural sources, such as plants, animals, or fungi. More often, the hits can come from synthetic sources, such as historical compound collections and combinatorial chemistry.

Recent developments in robotics and miniaturization have incredibly accelerated and automated the screening process. Typically, a company will assay over 100,000 individual compounds using a method called high-throughput screening (HTS), before moving to the optimization step.

Optimization
The second step of drug discovery involves the synthetic modification of the hits in order to improve the biological properties of the compound pharmacophore. The quantitative structure-activity relationship (QSAR) of the pharmacophore play an important part in finding lead compounds, which exhibit the most potency, most selectivity, best pharmacokinetics and least toxicity. QSAR involves mainly physical chemistry and molecular docking tools (CoMFA and CoMSIA), that leads to tabulated data and first and second order equations. There are many theories, being the most relevant Hansch's analysis that involves Hammett electronic parameters, Esteric parameters and logP parameters.

See also: ADME and Lipinski's Rule of Five

Development
The final step involves the rendering the lead compounds suitable for use in clinical trials. This involves the optimization of the synthetic route for bulk production, and the preparation of a suitable drug formulation.

Training in medicinal chemistry
Many workers in the field do not have formal training in medicinal chemistry. Graduate (postgraduate) level programs do exist in medicinal chemistry, but frequently the broader education in a chemistry graduate program can provide many of the skills needed.

可以到以下网站上找资料：

Pharmaceutical Chemistry Journal
http://www.springerlink.com/content/106490/
需要用户名和密码。文献求助版里以前有帖子发过，不知现在还能不能用。

EFMC（European Federation for Medicinal Chemistry）官方网站
http://www.efmc.info/

Safety-Directed Drug Design: Failures Are Successes


Scott Boyer
Safety Assessment
AstraZeneca R&D - 43183 Mölndal - Sweden
Tel: +46317762882
scott.boyer@astrazeneca.com

Few, if any, products undergo more safety testing and scrutiny than a pharmaceutical. This, of course, is essential as the most critical issue with regard to pharmaceuticals is the risk benefit ratio. Whilst patient benefits can be quite clear in most cases, the risk of undergoing a treatment regimen must be as carefully and broadly quantified as possible. Often this characterisation results in findings that result in discontinuation or withdrawal. Thus as drug withdrawals and experimental therapeutics that do not fulfil safety criteria during preclinical and clinical trials are regarded as ‘failures’, they are actually successes for patient safety and for the science base of drug discovery. The lessons learned and the data gathered during this sometimes painful process is of critical importance in buttressing future efforts against similar problems.

The failure of a drug or clinical candidate is invariably associated with a massive amount of basic science that goes into problem-solving activities. This effort, if captured and integrated into the Discovery process, can contribute to the development of better and more sophisticated approaches to discovery safety assessment and meaningful refinements in the regulation of drug development and approval. Thus, the resources and momentum behind a problem solving effort, particularly around a late-stage clinical candidate present a unique opportunity to develop a more stable and valid science base upon which to build a more rational approach to discovery safety.